Critical assessment of influenza VLP production in Sf9 and HEK293 expression systems by Thompson, Christine M. et al.
Titre:
Title:
Critical assessment of influenza VLP production in Sf9 and HEK293 
expression systems
Auteurs:
Authors:
Christine M Thompson, Emma Petiot, Alaka Mullick, Marc G Aucoin, 
Olivier Henry et Amine A Kamen
Date: 2015
Type: Article de revue / Journal article
Référence:
Citation:
Thompson, C. M., Petiot, E., Mullick, A., Aucoin, M. G., Henry, O. & Kamen, A. A. 
(2015). Critical assessment of influenza VLP production in Sf9 and HEK293 
expression systems. BMC Biotechnology, 15. doi:10.1186/s12896-015-0152-x
Document en libre accès dans PolyPublie
Open Access document in PolyPublie
URL de PolyPublie:
PolyPublie URL:
https://publications.polymtl.ca/3469/ 
Version: Version officielle de l'éditeur / Published versionRévisé par les pairs / Refereed
Conditions d’utilisation:
Terms of Use: CC BY
Document publié chez l’éditeur officiel
Document issued by the official publisher
Titre de la revue:
Journal Title:
BMC Biotechnology (vol. 15)
Maison d’édition:
Publisher:
Springer
URL officiel:
Official URL:
https://doi.org/10.1186/s12896-015-0152-x
Mention légale:
Legal notice:
Ce fichier a été téléchargé à partir de PolyPublie, 
le dépôt institutionnel de Polytechnique Montréal
This file has been downloaded from PolyPublie, the
institutional repository of Polytechnique Montréal
http://publications.polymtl.ca
RESEARCH ARTICLE Open Access
Critical assessment of influenza VLP production in
Sf9 and HEK293 expression systems
Christine M Thompson1,2, Emma Petiot1,3, Alaka Mullick1, Marc G Aucoin4, Olivier Henry2 and Amine A Kamen1,5*
Abstract
Background: Each year, influenza is responsible for hundreds of thousand cases of illness and deaths worldwide.
Due to the virus’ fast mutation rate, the World Health Organization (WHO) is constantly on alert to rapidly respond
to emerging pandemic strains. Although anti-viral therapies exist, the most proficient way to stop the spread of
disease is through vaccination. The majority of influenza vaccines on the market are produced in embryonic hen’s
eggs and are composed of purified viral antigens from inactivated whole virus. This manufacturing system, however,
is limited in its production capacity. Cell culture produced vaccines have been proposed for their potential to
overcome the problems associated with egg-based production. Virus-like particles (VLPs) of influenza virus are
promising candidate vaccines under consideration by both academic and industry researchers.
Methods: In this study, VLPs were produced in HEK293 suspension cells using the Bacmam transduction system
and Sf9 cells using the baculovirus infection system. The proposed systems were assessed for their ability to
produce influenza VLPs composed of Hemagglutinin (HA), Neuraminidase (NA) and Matrix Protein (M1) and
compared through the lens of bioprocessing by highlighting baseline production yields and bioactivity. VLPs from
both systems were characterized using available influenza quantification techniques, such as single radial
immunodiffusion assay (SRID), HA assay, western blot and negative staining transmission electron microscopy
(NSTEM) to quantify total particles.
Results: For the HEK293 production system, VLPs were found to be associated with the cell pellet in addition to
those released in the supernatant. Sf9 cells produced 35 times more VLPs than HEK293 cells. Sf9-VLPs had higher
total HA activity and were generally more homogeneous in morphology and size. However, Sf9 VLP samples con-
tained 20 times more baculovirus than VLPs, whereas 293 VLPs were produced along with vesicles.
Conclusions: This study highlights key production hurdles that must be overcome in both expression platforms,
namely the presence of contaminants and the ensuing quantification challenges, and brings up the question of
what truly constitutes an influenza VLP candidate vaccine.
Keywords: Influenza vaccines, Virus like particles (VLPs), Insect cells, Mammalian cells, Process development,
VLP characterization
Background
As reported by the World Health Organization, seasonal
influenza is responsible for approximately 500 million cases
of infection and between 250,000 to 500,000 deaths each
year [1]. Currently, vaccination remains the most proficient
strategy to prevent infection and to battle the persistent
threat of influenza epidemics. Egg-based production has
remained the standard method to produce seasonal influ-
enza vaccines since the 1950s; however, the serious threat
of an outbreak of pandemic avian flu and the influenza
H1N1 pandemic of 2009 have highlighted the limitations
associated with this manufacturing method [2,3]. These
drawbacks include the dependence on the availability of
eggs for production and their associated limitations with
regards to scalability (approximately 1 vaccine dose per
egg), the relatively long 6-month period from strain isola-
tion to final dose formulation and validation [4], and the
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based production has been proposed to overcome such
limitations; these processes are easier to scale-up and,
through the standardization of production methods, allow
for increased vaccine production. Moreover, cell culture
processes have the potential to reduce manufacturing time
by several weeks with a faster start-up time [5].
Seasonal influenza vaccines derived from cell culture
are gaining increased attention. In November 2012, the
first seasonal vaccine produced in cell culture (Flucelvax,
Novartis) was approved by the FDA. In January 2013, the
first trivalent influenza vaccine, Flublok (Protein Science
Corporation) made in insect cells using a recombinant
baculovirus expression system, was also approved. These
recent advances reflect an important trend of adopting
modern cell culture manufacturing in the influenza vac-
cine industry. It is highly supported by public health and
regulatory agencies that promote strategies to improve re-
sponses to emerging infectious diseases.
One of the most promising approaches is the use of
recombinant-based virus-like particle (VLP) vaccines [6,7].
Influenza VLPs are non-infectious and non-replicating
empty viral particles lacking viral genetic material, which
display intact and biochemically active antigens on their
surface. They can be composed of one, or different combi-
nations, of the viral antigens and structural influenza pro-
teins: HA, NA, M1 and M2 [6,8-11].
Immunizations with influenza VLPs to protect against
either seasonal or pandemic influenza strains have
shown promising results [8,12-14]. VLPs have a stronger
safety profile than native infectious viruses produced ei-
ther in egg-based or cell-based systems. No infectious
virus potentially harmful to humans is used as a seed in-
oculant or produced, thus production processes do not
require the use of high level containment facilities. With
more clinical trials underway for VLP vaccines [15,16],
there is a critical need for the scientific and engineering
communities to tackle the specific challenges associated
with the bioprocessing aspects of VLP production.
Thus far, different production processes have been
studied for influenza VLPs. They vary according to the
viral strain produced, the type of gene delivery system
used and the host-cell expression system. Influenza VLPs
have been produced in mammalian, insect and plant cell
platforms using a variety of vectors and gene delivery
techniques [17-19]. The majority of VLP productions
have been done in insect cells with the baculovirus ex-
pression vector system (BEVS) [8,18,20,21]. However,
this system suffers from contamination with baculovirus
(BV) particles [14,22] in final vaccine preparations. This
contamination has been known for a long time and can
represent up to 5% of the total proteins in final purified
VLP preparations [14] and 4.5 × 106 BEVS per vaccine
dose [22]. Baculovirus are non-replicative in mammaliancells, but they have been reported to trigger an innate im-
mune response. Although there is some evidence that
baculovirus is safe for immunization [22,23], in terms of
process development and evaluation of the immunization
efficiency from VLPs alone, such high level of contaminant
presents a problem. Alternative methods of VLP produc-
tion in mammalian cells, using either plasmid transfection
or baculovirus gene transfer in mammalian cells (BacMam)
have thus been developed. The second problem posed by
the insect cell platforms is product glycosylation, as insect
cells do not allow proper sialylation of the proteins [24].
Different groups are now working on the introduction of
such glycosylation pathways in insect cell systems.
Most studies thus far have focused on the proof of con-
cept of VLP production and the evaluation of influenza
VLPs immunogenicity to support their candidacy as po-
tential vaccines [8,12] and as a model to gain insight into
the requirements for influenza virus budding [25]. Never-
theless, to date, limited attention has been paid to the spe-
cific challenges posed by the manufacturing of VLPs.
However, studies of this nature are starting to surface
[18,19,22,26].
In line with the theme of studying the bioprocessing of
influenza VLPs, this study assessed two platforms for VLP
production, the insect (Sf9) and mammalian (HEK293)
suspension and serum-free production platforms with in-
fluenza gene transfer by baculovirus infection and trans-
duction, respectively. VLP production and contaminant
levels (VLP/mL, BV/mL, μg HA/mL, HA units/mL), as
well as the challenges associated to each production sys-
tems are discussed.
Methods
Cells and medium
The HEK293 cell line used for VLP production was pre-
viously adapted to suspension and serum-free culture
[27]. Working cell banks were made from a vial of the
master cell bank, which was developed under Good
Manufacturing Practices (GMP). HEK293 cells used for
VLP production were grown in shake flasks at 37°C and 5%
CO2, in animal component and serum free SFM4Transfx
293™ (HyQ) medium (HyClone, Waltham, MA, USA). In-
sect Spodoptera frugiperda (Sf9) cells were maintained in
serum free Sf900 II medium (GIBCO, Burlington, ON,
Canada), in shake flasks at 27°C with an agitation rate set
at 110 rpm. Cell density was monitored using the Cedex
Cell Counter (Innovatis Roche Applied Science, Penzberg,
Germany).
Construct design of the gene transfer system
Baculovirus BacMam for mammalian cell production system
(HEK293)
The recombinant baculovirus used for HEK293 cell
transduction (referred as BacMam PR8) was previously
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Ted Ross (University of Pittsburgh). One recombinant
baculovirus was used to drive the expression of HA, NA
and M1 genes from H1N1 A/Puerto Rico/8/1934 influ-
enza strain under the control of individual CMV pro-
moter. BacMam PR8 also contained a Green fluorescent
protein (GFP) reporter gene under the CMV promoter
and a VSV-G protein under polyhedron promoter control
in order to improve cell transduction. A working stock of
BacMam PR8 baculovirus was produced by generation of
P0 BacMam PR8 stock in Sf9 cells with bacmid transfec-
tion and two subsequent BacMam PR8 amplifications in
Sf9 cells (the VP/mL and IVP/mL of each stock can be
found in the Additional file 1: Table S1).
Baculovirus construction for insect cells production system
(Sf9 cells)
For production in insect cells, co-infection with three
baculoviruses each carrying influenza proteins, HA, NA
or M1 was chosen. The influenza proteins were under
polyhedron promoter (polh) control for expression in in-
sect cells. The construction of vectors for further gener-
ation of P0 baculovirus stocks through Sf9 cells
transfection was performed as follows: the DNA sequence
of H1N1 A/Puerto Rico/8/1934 HA (AB671289.1), NA
(AB671290.1) and M1 (CY033578.1) were obtained from
NCBI’s influenza database. Influenza gene sequences were
inserted between XbaI and BglII enzyme restrictions sites
and further in a pUC plasmid by BioBasic (Markham,
Canada). Each influenza gene, flanked by XbaI and BglII
sites, was further inserted in the pVL1393 plasmid, be-
longing to the commercial BaculoGold™ system (BD bio-
science, Franklin Lakes, USA) used for the construction of
baculovirus allowing expression of recombinant proteins
in Sf9 cells. Each of the three plasmids, respectively named
pVL1393-HA, pVL1393-NA and pVL1393-M1, were co-
transfected with baculovirus DNA to produce recombin-
ant baculoviruses referred to as Bac-HA, Bac-NA, and
Bac-M1. Similarly, to produce the BacMam PR8 virus
stock, each Bac-HA, Bac-NA and Bac-M were passaged
twice in Sf9 cells to produce a P2 working viral stock used
for VLP production (VP/mL and IVP/mL of each stock
can be found in the Additional file 1: Table S1).
VLP production
For both cellular platforms, during the production optimization
phases, cultures were sampled once to twice a day and cell
density, viability and average cell diameter were measured
using the Cedex Cell Counter (Innovatis Roche Applied
Science, Penzberg, Germany).
Mammalian HEK293 cell platform
For VLP production in HEK293 cells, transduction with
BacMam PR8 was performed at a cell density of 1.5-2.0×106 cells/ml. An MOI of 60 was used (MOI calcula-
tions were based on infectious baculovirus titers). Produc-
tion runs were carried out in shake flasks with working
volumes of 60–400 ml. In production runs, butyric acid
was added at a final concentration of 5 mM at the time of
infection. After 48 hours post-infection, culture broth
samples were clarified by slow centrifugation at 300 × g
for 5–10 minutes. Culture supernatant samples were
concentrated via sucrose cushion ultracentrifugation and
analysed by Western blot, HA assay, Negative Stain
Transmission Electron Microscopy (NSTEM) and Single
Radial Immuno-diffusion assay (SRID).
Insect Sf9 cell platform
VLP productions in Sf9 cells were performed in shake
flasks with working volumes of 60–400 ml. Cells were
infected with P2 working stocks at a density of 2.0-2.5 ×
106 cells/ml with a total MOI of 0.3-2.1 at 27°C (MOI
calculations were based on infectious baculovirus titers).
Cells were harvested after 48 hours post-infection, when
the viability started to decline below 70-50%. Upon har-
vest, the supernatant samples were collected with slow
centrifugation at 300 × g for 5–10 minutes, then con-
centrated via sucrose cushion ultracentrifugation and
analysed by Western blot, HA assay, NSTEM and SRID.
VLPs extraction from cell pellet
The cell pellets obtained after slow centrifugation were re-
suspended in a solution of PBS and 10 μg/ml of TPCK-
trypsin and slowly agitated at 37°C for 30 minutes to
produce cell pellet wash. Cells were pelleted via slow cen-
trifugation and the supernatant was collected for analysis
by Western blot, HA assay and NSTEM. A cell lysis ex-
traction was also performed after this first treatment by
one freeze-thaw cycle. The cell lysis supernatant was col-
lected by centrifugation at 1000 × g for 5 min and then
analysed using Western blot, HA assay and NSTEM.
Influenza virus production
Influenza H1N1 A/PR/8/1934 virus was produced in
house as described in Petiot et al. [28] and used as stand-
ard for the Western blot, HA assay and NSTEM images.
VLP concentration and purification
Sucrose cushion ultracentrifugation
The VLP supernatants were sublayered with 10 ml of a
25% sucrose solution prepared in 20 mM Tris–HCl
(pH 7.5). The maximal VLP volume loaded was of 200 ml
of culture supernatants, centrifuged at 4°C and 37 000 × g
for 3 hours (Sorvall Discovery SE 100 ultracentrifuge,
A621 rotor, Thermo Scientific, Waltham, USA). The ultra-
centrifugation supernatants were discarded and the VLPs
were collected as pellets, re-suspended in 20 mM Tris–
HCl, 1% sucrose and 2 mM MgCl2. Ultracentrifugation
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quoted and stored either at −80°C or 4°C. This purifica-
tion step allowed to concentrate VLP production samples
up to 20-75×.Iodixanol gradient ultracentrifugation
Gradient iodixanol purification was done from two
working stock solutions of iodixanol, one with 40% w/v and
one with 25.5% w/v. These solutions were prepared from
Optiprep iodixanol solution (Axis-Sheild, Oslo, Norway)
with 60 mM Tris–HCl (pH 7.5). VLP concentrated solu-
tions from the sucrose cushion purification step were
combined to the 25.5% iodixanol working stock and
subjected to slow mixing to give a final iodixanol concen-
tration of 20% and a VLP dilution of 4.7×. The VLP-
iodixanol solution was then loaded into 13 ml ultracentrifuge
tubes, sealed and centrifuged at 350 000 × g for 6 hours at
4°C (Sorvall Discovery SE 100 ultracentrifuge, 65 V13
rotor, Thermo Scientific, Waltham, USA). After ultracen-
trifugation, 1 ml fractions were taken from the bottom of
the tubes and weighed to determine the density and iodix-
anol concentration. Each fraction was then analysed by
Western blot, HA assay and NTSEM.VLP quantification and detection
Western blot
Samples were loaded on a Bio-Rad mini-protean Tris-
Glycine 4-15% gel with 1× running buffer (25 mM Tris,
192 mM Glycine, 3.5 mM SDS). The gel was run for
40 minutes at 200 V and then washed with Towbin
transfer buffer (25 mM Tris, 192 mM Glycine, 20%
Methanol pH 8.3). Semi-dry protein transfer to nitrocel-
lulose membrane was performed using a Bio-Rad Trans-
Blot 3D semi-dry transfer cell (Hercules, CA, USA) for
1 hour at 10 V. Membranes were then blocked for 1 hour
in 5% milk solution (1× TBS, pH 7.5: 50 mM Tris,
150 mM NaCl, 0.1% Tween-20, 5% milk). The mem-
brane was washed with 0.1% Tween TBS at pH 7.5 and
then incubated overnight at 4°C with its respective antibody
(conc. 1/1000). The secondary antibody incubation (conc.
1/1000) lasted 1 hour at 4°C. Primary antibodies used for
HA, NA, M1 and GP64 were as follows: anti-HA and anti-
NA, polyclonal sheep serum (ref. 03–242 and 04–230,
respectively, NIBSC, London, UK); anti-HA monoclonal
mouse (ref. sc-80550, Santa Cruz Biotechnology, USA);
anti-M1 monoclonal mouse antibody (ref. ab22396, Abcam,
Cambridge, USA); anti-GP64 monoclonal mouse anti-
body (ref. 14-6995-81, eBioscience, San Diego, USA).
The secondary antibodies used were Donkey anti-sheep
and Donkey anti-mouse (ref. 713-005-003, 715-005-150,
respectively) IgG HRP from Jackson ImmunoResearch
(Westgrove, USA). Images were acquired with a DS
Image Station 440CF (Kodak, Rochester, USA).Hemagglutination assay
The HA assay was completed in 96 well v-bottom plates.
Wells were filled with 100 μl of 1× PBS solution in rows
A-H, columns 2–12. Next, 29.3 μl of 1× PBS was loaded
into wells B1, B2, D1, D2, F1, F2, H1 and H2. Each sam-
ple took up two rows (A and B, C and D, etc.) and was
serially diluted with VLP samples from the supernatant,
sucrose cushion and iodixanol purifications. 100 μl of
VLP sample was loaded into wells 1 and 2 of rows A, C,
E, and G, then 70.7 μl into wells 1 and 2 of rows B, D, F
and H. The VLP sample was then serially diluted and
100 ul of 5-day old chicken red blood cells at a concen-
tration 2×107 cell/ml were added to each well in the
plate. The plates were left in a covered plastic container
for 3 hours to overnight at room temperature and
scored. The amount of HA in units HA/ml was calcu-
lated with the following correlation:
Log HA units
100 ul
¼ log dilution factor at last well agglutinatedð Þ
Single radial immunodiffusion assay
A 1% agarose gel solution was prepared and equilibrated
at 50°C in a water bath. Agarose gel solution was added
with anti-HA sheep serum (ref. 03–242, NIBSC, London,
United Kingdom) with a final concentration of 1/1000.
The agarose-antibody mixture was casted and left to cool
in a Bio-Rad gel-casting module for at least 15 minutes. In
the gel, 4 mm wells were punched before addition of 20 μl
of sample in each well. For all the SRID experiments, a
calibration curve was determined with standard samples
of purified recombinant HA of A/H1N1/Puerto Rico/8/
1934 strain from Protein Sciences Corporation (Meriden,
USA) at concentrations ranging from 7 to 30 μg/ml. All
the samples were subjected to detergent treatment for
15 minutes on a rocker platform (1% Zwittergent final
concentration). Sample diffusion in the gel took place for
18–24 hours at room temperature. The gel was dried
using Whatman #3 filter paper (Kent, United Kingdom),
rinsed with deionized water, and stained with Coomassie
Blue R-250 for 15 minutes and de-stained using a 7.5%
acetic acid and 10% ethanol solution. Result analyses were
performed on gel photograph where the diameter of the
reference standards and samples were measured using
Image-J software (Pixel-aspect ratio = 1, known distance
= 4 mm) allowing further calculation of sample concen-
tration through linear correlation.
Negative Stain Transmission Electron Microscopy (NSTEM)
NSTEM analysis were conducted at Institut Armand
Frappier (Laval, Canada) adapting a method previously
described [29]. For each samples, 2 micrographs were
counted with samples pre-diluted to have at least 25
VLPs on the grid. The range of VLPs counted was
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quantified using the following equation: VLP/ml = (VLP
count/latex bead count) × (latex bead concentration ×
virus dilution).Results and discussion
It is important to note that, for all the analysis per-
formed (NSTEM, Western Blot, HA assay, SRID), the
samples were concentrated by a sucrose cushion ultra-
centrifugation step. This concentration step was neces-
sary as the available quantification methods are not
sensitive or specific enough to directly quantify total
VLPs and protein composition of non-purified culture
supernatants. This allowed us to i) reach detectable
levels and ii) and reduce the contamination by free influ-
enza and host cell proteins in the sample. Consequently,
most of the assays were performed with at least a 40×Figure 1 NSTEM images at 40,000× magnification of H1N1 A/Puerto Rico/8
(C-G) or Sf9 cell production (H-J). VLPs or influenza virus are pointed by bl
& B - Supernatant of H1N1 A/Puerto Rico/8/1934 influenza virus produced
carrying influenza glycoproteins could be identified. C, D & E - Sucrose cus
zoom-in (D & E) images of NSTEM grid. F & G - Iodixanol purified samples
identified in high density (fraction 12: 1.03 g/ml) and low density (fraction
cell production. J - Iodixanol purified samples fraction 3, which present the
VLPs in all the iodixanol fractions, even if they were more concentrated inconcentrated sucrose cushion purified samples and all
the values presented in the paper correspond to their
relative normalized production levels (per/mL).VLP morphology and particle quantification
Influenza virus and VLP morphology were analysed by
visual inspection on NSTEM micrographs, and the con-
centration of VLP particles were assessed for the com-
parison of VLP production efficiency in both cellular
platforms. Previous studies of influenza virus production
in HEK293 cell culture described the virus as pleo-
morphic particles containing spikes with an average size
of 100 +/− 20 nm [30]. Influenza virus consisted mainly
of spherical and elongated particles [31]. An example of
H1N1 A/Puerto Rico/8/1934 influenza viruses produced
in-house on the same HEK293 cell platform [31] is
shown in Figure 1. On this basis, VLPs were defined as/34 (A & B), H1N1 influenza-VLPs from HEK 293SF cell production
ack arrows, baculovirus and cell vesicles are pointed by white arrows. A
in HEK 293SF suspension cells as in Petiot et al. [28]. Cell vesicles
hion purified samples of HEK 293SF cell production; large view (C) and
of HEK 293SF cell production. Typical shapes of VLPs and vesicles
2:) iodixanol fractions. H & I - Sucrose cushion purified samples of Sf9
highest number of VLP particles. Baculovirus were co-purified with
the high density fractions.
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sumed to be influenza glycoproteins HA and NA, with a
size range of 100 +/− 50 nm. NSTEM images of VLPs
produced with both HEK293 SF and Sf9 cells are shown
in Figure 1. Pictures presented are all from purified sam-
ples, either sucrose cushion (C, D, E H & I) or sucrose
cushion and iodixanol purified (F, G & J).
Figure 1D, E & F present zoomed-in images of VLPs
produced with HEK293 cells. The VLPs were similar to
influenza virus particles, although their average size
ranged from 100 to 500 nm and they displayed the typ-
ical morphology of host cell vesicles. VLPs were counted
to be at a concentration of 1.5 × 108 VLPs/ml.
Figure 1I & J present zoomed-in images of VLPs pro-
duced in Sf9 cells. Their morphology seems to be uni-
form and close to influenza virus, consisting of spherical
particles with an average size close to 100 nm. For these
samples, a concentration of 5.85 × 109 VLPs/ml was
quantified for Sf9 VLP production.Figure 2 Western blot of Sucrose cushion VLP samples from HEK 293SF an
monoclonal Abs against HA2 (Santa Cruz, sc-80550) and a polyclonal antib
blot using anti-NA NIBSC sheep (04–230). C - Anti-M1 western blot using mVLP composition
VLPs were expected to contain HA, NA and M1 influ-
enza proteins. HA and NA are the antigen proteins
located on the particle surface and M1 is the matrix pro-
tein that is the structural backbone of the viral particle.
M1 is assumed to be located on the internal surface of
the membrane envelope. For both production systems,
VLP samples recovered in the culture supernatant and
pre-purified by sucrose cushion were examined by West-
ern blot. The presence of HA and NA in sucrose cushion
was confirmed for VLPs produced in both the HEK293
and Sf9 cell platforms (Figure 2A & B). Surprisingly, M1
was present in the Sf9 VLPs but not found in HEK293
VLP samples (Figure 2C).
In order to confirm expression of M1 in HEK293 cells,
anti-M1 Western blots of cell pellet were performed on
both Sf9 and HEK293 cells (Figure 2C). M1 protein was
present in both cell pellets, albeit in higher quantities in
the Sf9 pellet than in HEK293. This indicated that M1d Sf9 cells. A - Anti-HA western blot with two different antibodies, a
ody against HA0 (anti-HA NIBSC sheep; 03–242). B - Anti-NA western
onoclonal mouse antibody (Abcam, ab22396).
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into the VLPs. Integration of M1 into the Sf9 VLPs could
explain for the more spherical and uniform particle shape
observed with this system. M1 has been known for a long
time to play an important role in determining the shape of
influenza particles, especially for the formation of filament-
ous or spherical types of viral particles [32-34]. The M1
protein affects influenza virus morphology in a number of
ways; firstly though a number of its amino acid residues
[34] that interact with both HA and NA to drive the bud-
ding process [35]; and secondly, with interactions with the
NP protein and the vRNP complex [36].
Studies of bud formation and viral particle morphology
from the last decade proved that M1 is not the sole protein
playing a role in viral particle formation and their morph-
ology. The M2 protein, which is an ion channel protein,
contains a highly conserved tail among different viral
strains that was not necessarily responsible for their specific
activity, but was later related to budding efficiency and par-
ticle morphology [35,37]. Besides influenza itself, host-cell
heat-shock protein 70 (Hsp70) has also been described to
play an important role in bud formation [38]. Actin was
also reported in different studies as potentially impacting
the virus produced shape [34], and a number of other cellu-
lar proteins of Vero cells have been recently detected in A/
WSN/33 H1N1 influenza virions produced in this system
[39]. It has also been shown for different insect cell produc-
tion platforms tested (Sf9 versus Tn5 cells), that the cell
type has a great impact on homogeneity of the VLPs pro-
duced [24]. Consequently, the cellular platforms used for
either influenza virus or VLP production, and their mem-
brane compositions, are expected to have a great impact on
the quality of VLPs produced.
A careful review of previous influenza VLP studies indi-
cated many contradictory results. Most of the influenza-
VLP production studies consider that M1 is an important
factor for correct VLP budding and is integrated into
most of the constructions [19]. Chen et al. have shown
that co-expression of M1 and HA proteins increases VLP
production, rather than HA expressed alone [25]. But
other studies have demonstrated that VLPs without M1
can be successfully produced, such as VLPs produced inTable 1 Summary of the production performances for the two
cells
Sucrose cushion samples
Cell line HA protein
activity
(HA assay)
HA protein
content
(SRID assay)
VLP conc.
(NSTEM)
Bacu
cont
(NST
Insect Sf9 335 HAU/ml 0.38 μg/ml 5.85 × 109 VLPs/ml 1.12
Mammalian
HEK 293
13 HAU/ml 0.092 μg/ml 1.50 × 108 VLPs/ml 3.07
Iodixanol fractions presented for both systems are the ones containing more VLP p
HEK293SF cells. It should be noticed that for Sf9 and HEK293SF cells, sucrose cushio
fractions of 110 times and 140 times. The values presented in this table represent tHEK293T cells that only contain NA from both H5N1
and H1N1 strains [40]. Finally, M1 was also shown to
form VLPs on its own in COS-1 and Sf9 cells [12,41].
This observation confirms the importance of the cellular
platform on the level of incorporation of M1 in the VLPs
and on particle formation, which appears to be cell line
and expression system dependent.
VLP HA activity
The particles produced as VLPs by both systems were
also evaluated for their activity. The HA assay was
performed to demonstrate the agglutination activity of
sucrose cushion purified VLPs and the HA protein con-
tent (μg/ml) was evaluated by the standard quantifica-
tion method used for influenza vaccine dose release, that
is the SRID assay. Results are presented in the compara-
tive Table 1. For the HEK293 cell production system,
VLPs reached HA titers of 13 HAU/ml whereas for Sf9
cell produced VLPs, the HA activity was at 335 HAU/
ml, which is more than 25 times higher. As for HA pro-
tein content, results obtained for HEK293 cells were
again lower than the Sf9 cell system, with a production
level of 0.092 μg HA/ml for HEK293 VLP samples and
0.38 μg HA/ml for Sf9 VLP samples (4-fold increase). It
is interesting to note from a product qualification point
of view that the ratio of total VLPs counted from both
systems is not correlated to the results obtained from
the SRID and HA assay. This is due, as discussed in a
previous review of influenza-VLP quantification methods
[42], to the particularity of each quantification method
and their intrinsic bias. It should be emphasized that
the hemagglutination or SRID assays, routinely used to
quantify VLPs in past studies, do not have the ability
to make a distinction between real virus-like particles
and impurities [19,22]. Vesicles or baculovirus carrying
HA proteins will be quantified the same way by such
methods. Presently, only visual direct identification will
allow for a reliable assessment of the influenza-VLP
particle produced from each cellular platform. That is
why this work also presents elements to qualitatively
assess the purity by direct visual inspection of the
samples by NSTEM in the following section.cell platform, Sf9 insect cells and HEK293SF mammalian
Iodixanol purified samples
lovirus
amination
EM)
HA protein
activity
(HA assay)
VLP conc.
(NSTEM)
Baculovirus
contamination
(NSTEM)
× 1011 BV/ml 32.4 HAU/ml 2.39 × 109 VLPs/ml 1.73 × 1010 BV/ml
× 107 BV/ml 8.11 HAU/ml 7.71 × 107 VLPs/ml Not quantified
articles, i.e. fraction 3 for Sf9 cells (1.13 g/ml) and fraction 1 (1.16 g/ml) for
ns were concentrated respectively of 40 times and 50 times, and for iodixanol
he production levels (i.e. non concentrated samples).
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Zoomed-out images of sucrose cushion purified VLPs
for both Sf9 cells and HEK293 cells are presented in
Figure 1C & H.VLP purity
For Sf9 cell productions, influenza-VLPs are identified
by black arrows in Figure 1H. However, co-produced
baculoviruses are also clearly identifiable in the picture
(rod shaped particles, indicated by white arrows). Bacu-
loviruses counted in this NSTEM micrograph sample
were at a concentration of 1.12 × 1011 BV/ml, which
corresponds to 20 times more than influenza-VLPs.
In order to further purify influenza-VLPs from baculo-
viruses, iodixanol gradient ultracentrifugation was ap-
plied and a picture of the third fraction collected
(density: 1.13 g/ml) is shown on Figure 1J. Baculovirus
contamination is still visible and present at a concentra-
tion of 1.73 × 1010 BV/ml. As a confirmation, in both
sucrose cushion and further iodixanol purified samples,
the presence of envelope protein GP64 from baculovirus
was observed on Western blot analysis (data not shown).
Several previous studies have reported the presence of
baculovirus contamination in VLP samples produced ei-
ther in Sf9 or High Five cell production platforms. The
level of baculovirus contamination ranged from 106 to
108 PFU/ml [18,22] as measured by plaque assays, which
is significantly lower than the one found here. In the
present work, a visual assessment of baculovirus present
in the sample was preferred in order to show the total
contamination present and to have a better correlation
with visual VLP quantification. Baculovirus contamin-
ation in the influenza-VLP product poses a significant
problem, as these viruses share structural and biophysical
similarities with influenza-VLPs, thereby complicating
the development of efficient and appropriate purification
processes [24,26].
As previously mentioned by Tang et al., the main mo-
tivation behind producing VLPs in HEK293 cells was to
avoid or reduce the baculovirus contamination [19]. In
our case, and as expected, baculoviruses were present in
much smaller amounts in HEK293 production samples.
However, another kind of contamination was visible on
HEK293 VLPs images. Cell or particle debris (dark clus-
ters) as well as large vesicles size (>200 nm) carrying the
characteristic influenza fringe can be seen. The presence
of cell vesicles may also complicate purification steps in
downstream processing, resulting in a similar contamin-
ation problem that exists with VLP production in the
baculovirus-insect cell system (similar size of particles,
vesicles carrying HA). When purified by iodixanol gradi-
ent, cell vesicles are also co-purified with lower size
influenza-VLPs. Nevertheless, as indicated by the picture1-G, high-density fractions were concentrating large cell
vesicles (>300 nm).
Downstream processing and purification have now been
repeatedly pointed out as a critical step and a bottleneck in
the development of such new antigen design for a number
of different VLPs production types [24,43]. But our obser-
vations and those of others raise additional concerns: i) the
correct cut-off size for particles to be qualified as VLPs and
ii) the immune response generated from co-produced vesi-
cles as it is the case of contaminating baculoviruses.
VLP recovery
As we applied a concentration step by sucrose cushion
ultracentrifugation prior to NSTEM analyses, in order to
detect and count enough material, it was quite difficult
to evaluate the proportion of VLPs recovered from each
production. Although ultracentrifugation is a method
broadly used to purify VLPs, it has the potential to be
damaging for fragile particles. To our knowledge, VLP
stability during this process has not yet been evaluated.
Nonetheless, the most likely explanation for such a
high level of debris in HEK293 cell sucrose cushion sam-
ples (Figure 1D), considering that cell viability was com-
parable in both production systems, is that some VLPs
or vesicles were disrupted by the ultracentrifugation
step. The images of VLPs produced in HEK293 cells
showed more debris than those of VLPs produced in Sf9
cells. This might be due to the fact that VLPs produced
by HEK293 cells were more fragile than those produced
in Sf9 cells. This might also be related to the observa-
tions previously made on the incorporation/lack of M1
in VLPs produced in Sf9 and HEK293 cells, suggesting
the importance of M1’s presence for VLP stability. Al-
though M1 may not be essential for VLP formation, the
present study suggests its importance from a bioproces-
sing standpoint and the associated need for stable parti-
cles able to withstand downstream processing steps.
In order to achieve higher recovery yields, especially in
the case of HEK293 cells, cell pellets from production
runs were also examined. Indeed, influenza-VLPs could
have been entrapped on cells due to the adhesion of HA
proteins to sialic acid cellular receptors. Additionally,
HEK293 cells were subjected to cell clumping, which
could eventually inhibit influenza-VLPs release from the
cell membrane.
First, pellets of HEK293 cells were washed with a solu-
tion containing trypsin to counteract cell clumping. Sec-
ond, cells were lysed. The cell pellet wash and lysate
were analysed by an HA assay and by NSTEM to reveal
the presence of VLPs. A treatment of the cell pellet with
exogenous neuraminidase was also tested, but no notice-
able effect was observed on VLP release from a pre-
screening with Western blot (data not shown). A wide
range of particles with a fringe were present in the
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images, including very large particles up to 500 nm
(Figure 3A). A cluster of round particles approximately
100 nm in diameter could clearly be identified as
influenza-VLPs. VLP concentration was counted to be
3.07 × 108 VLPs/ml. Particles with a fringe were also
present in the cell lysate at a concentration of 1.43 × 108
VLPs/ml, and looked very similar to those presented in
Figure 3A. HA assay confirmed that active HA protein
was released from the cell pellet wash and in the cell
lysate (Figure 3B).
Similar analyses of Sf9 cell pellet wash and cell lysate
did not demonstrate comparable HA activity to the super-
natant. This result was expected, as cell clumping did not
occur during production. These results indicate that, for
some cell production platforms, an extraction step prior
to harvest should allow to increase the final VLP yields.100 nm
Figure 3 NSTEM image at 40,000× magnification of cell pellet wash upper
with culture supernatant, cell pellet wash and lysate lower panel.Influenza particles are known to bud from the cell
membrane [44] and are expected to be found in the super-
natant. However, other viruses, such as HIV, were re-
ported to occasionally bud from internal multi-vesicular
bodies [45], even though they usually bud from the plasma
membrane. This explanation may hold some merit in our
case considering that i) more than one influenza protein
has the potential to induce budding [44], and ii) vesicles
carrying HA and/or NA identified as VLPs may also have
come from internal membranes and were released upon
cell death.
Comparison of cell platforms for VLPs production
From a basic point of view, this comparative study
suggests that the Sf9 system is a better production plat-
form. Indeed, it is more productive than the HEK293
system with 35 times more VLP particles quantified onpanel and HA activity for VLP samples produced in HEK293SF cells
Thompson et al. BMC Biotechnology  (2015) 15:31 Page 10 of 12NSTEM micrographs. The particle counts allow for com-
parison of cell specific productivity, as both mammalian
and insect cell runs were performed at 2.0-2.5 × 106 cells/
ml over a course of 48 hours. Therefore, the Sf9 system also
presents a significant advantage in terms of VLPs/cell prod-
uctivity. Moreover, VLPs produced in insect cells were
more homogeneous and resembled influenza particles pro-
duced in cell culture, whereas the VLPs produced in mam-
malian cells were heterogeneous in shape and size. These
observations were also confirmed by HA protein quantifi-
cation assays, which showed that the Sf9 cell samples had
approximately 25 times more HA activity and presented
higher amounts of HA concentration (μg/ml) than the
HEK293 cell production system.
However, this conclusion should be nuanced by the M1
protein results and purity evaluation. If the HEK293 cell
system could incorporate M1 into the influenza-VLPs, or
if other matrix proteins (e.g. murine leukemia virus struc-
tural gag) would have been explored, as already done pre-
viously [46], the outcomes may have been different. In
Haynes et al. [46], approximately 2×1012 VLP/ml were
produced compared to 2×108 PFU/ml of baculovirus.
The increased amount of VLPs from this system com-
pared to the present study (Table 1) could provide a
better starting point when considering downstream puri-
fication of contaminates and VLP recovery for an indus-
trial manufacturing process.
In addition to production yields and product quantifica-
tion, potential safety concerns must also be considered for
both production systems. Regarding cell vesicles released,
it is known that they perform a variety of functions in the
cell’s secretory pathway [47]. Vesicles may contain cell
waste, including proteins and nucleic acids. In vaccine
products, host-cell products are strongly controlled and
have to be quantified and/or inactivated as indicated in
regulatory agency guidelines. To our knowledge, the con-
tent of purified influenza VLPs and/or their accompanying
vesicles have never been thoroughly studied. Baculovirus
have also been proved to strongly initiate an immune re-
sponse in mice and present adjuvanting effects when
injected even at low levels with VLPs [22,48]. These effects
could either benefit and boost the vaccine efficacy or cre-
ate negative synergistic effects on the target VLPs im-
munologic response [26]. Study of baculovirus effect on
mammal’s immune system is still on-going [49], and it is
not presently possible to determine the safety of such con-
taminant in VLP products. Therefore, a lot of attention
should be dedicated to the separation of VLPs from
baculovirus contaminants.
Conclusions
In this work, we have characterized VLPs using a num-
ber of established influenza assays aiming to better com-
pare the production capabilities of two expressionplatforms. Such work is critical to understand and iden-
tify the bioprocessing challenges that still need to be ad-
dressed to further optimize VLP production. Moreover,
the present study provides a baseline for VLP produc-
tion values (Table 1) using HEK 293 and Sf9 expression
systems, an information critically missing in the prevail-
ing literature. Both systems were able to produce what is
referred to as VLPs in the literature. However, this work
has raised questions on what may be needed to produce
structurally sound influenza VLPs, contamination issues
that both systems face, and what should be defined as a
virus-like particle. Influenza VLP should be a particle
closely resembling influenza virus particles i.e. with the
same size and morphology with the exclusion of vesicles
from the cellular production system. From comparing
the two production systems, it was found that the Sf9
system produced VLPs at a level 35 times more than the
HEK293 system, however there remains the challenge of
baculovirus contamination. Additionally, two important
points should be underlined: Firstly, the incorporation of
M1 in the VLP may have a significant influence on the
integrity and size of VLPs produced, although further
work is needed to elucidate how M1 impacts VLP stabil-
ity. Secondly, the HEK293 system also presents contam-
inating cell vesicles, visible in a wide variety of sizes in
the cell supernatant.Additional file
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